Bispecific T Cell Engager (BiTE) targeting pan-Tissue microenvironment marker CD155
CD155-targeting bispecific T-cell engager (BiTE) that crosslinks T-cells to CD155-expressing cells to exploit the immunosuppressive tumour tissue microenvironment into a therapeutic advantage.
CD155 BiTE is comprised of anti-CD155 scFv x anti-CD3 scFv, which crosslinks T-cells to CD155-expressing cells to form pseudoimmune synapses where clustering of CD3 triggers the release of cytotoxic granulates to kill the CD155 expressing cells.
Applications: Cancer immunotherapy, gene therapies, oncolytic virotherapies
| Features | Benefits |
|---|---|
| Targets CD155, which is differentially expressed in the tissue microenvironment (TME) | Selective targeting of multiple cell types within TME in one go, but not healthy cells |
| Combines pan-TME marker CD155 with bispecific T cell engager | Allows exploitation of immunosuppressive nature of TME, depleting the TME from periphery to allow easier infiltration of immune cell and anti-cancer biologics into the tumour |
| Small size of BiTE | Prevents any on-target off-tumour effect, and rapid renal clearance if there is any entry to circulation |
| Stand alone or combination use | Use in combination with different gene therapies or oncolytic virotherapies |
Awaiting patent and Available For
- Co-development
- Consulting
- Licensing